Total revenue for the year ended December 31, 2025, was $49.897 million, a 0.5% increase from $49.667 million in 2024. Product revenue increased by 1.2% to $49.597 million, while service revenue decreased by 53.7% to $0.300 million. Gross profit increased by 2.1% to $21.700 million in 2025, with a gross margin of 43.5% (up from 42.8% in 2024). Selling, general, and administrative (SG&A) expenses decreased by 21.2% to $41.968 million in 2025, primarily due to reduced amortization from the MLB Promotional Rights Agreement termination and cost-cutting measures. Operating loss improved to $(20.268) million in 2025 from $(31.987) million in 2024. Net loss remained significant at $(29.741) million in 2025, compared to $(29.846) million in 2024. Cash and cash equivalents decreased to $8.035 million at December 31, 2025, from $22.618 million at December 31, 2024. The company launched new product lines including functional mushroom gummies and Brightside low-dose THC gummies, featuring TiME INFUSION rapid-onset technology. DeFloria, a joint entity with AJNA BioSciences and BAT, received FDA notification to proceed with Phase 2 human clinical trials for AJA001 Oral Solution, a botanical drug for autism spectrum disorder. The company will participate as a CBD provider in a Medicare and Medicaid pilot program for senior oncology patients in early 2026. A significant transaction with BAT was announced on March 30, 2026, involving the conversion of BAT's C$75.3 million convertible debenture and accrued interest into common shares at C$0.94 per share, plus an additional $10 million equity investment, totaling approximately C$103 million ($75 million) and resulting in the issuance of approximately 110 million common shares to BAT. The federal definition of hemp was revised in November 2025, effective November 12, 2026, to limit total THC concentration (including THCA) to 0.3% on a dry weight basis for hemp and intermediate products, and 0.4 milligrams of total THC per container for final products, which could negatively impact a large percentage of existing full-spectrum hemp products. The company completed full internalization of Brightside gummy production, enhancing quality control and supply chain resilience. The SBH Purchase Option to acquire Stanley Brothers USA Holdings, Inc. expired unexercised on February 26, 2026.